Gattaca

The fiction defines the nightmare. The table scores what reality has already built — each symptom checkable, each status sourced, the absences counted as honestly as the arrivals.

The symptoms

	symptom	the evidence	as of
✅	Embryo polygenic screening for disease risk sold to prospective parentspresent	Preimplantation polygenic testing (PGT-P) has been sold since Genomic Prediction launched it in 2019. MIT Technology Review reported (12 Jan 2026) that PGT-P is now offered at over 100 US fertility clinics, with Orchid, Herasight and Nucleus among the providers, scoring IVF embryos for risk of conditions such as diabetes, cancer and heart disease. [source]	2026-01
◐	Embryos ranked and 'optimized' for non-disease traits (intelligence, height, appearance)partial	Nucleus Genomics launched 'Nucleus Embryo' (~$5,999) in June 2025, ranking IVF embryos on intelligence, height, BMI, and eye and hair colour; it drew an ethics backlash (TechCrunch, 6 Jun 2025). The National Human Genome Research Institute and geneticists note polygenic scores are population statistics with weak per-embryo predictive power. The product is sold; the destiny it implies is not validated. [source]	2025-06
◐	Whole-genome readout taken at birth (the film's blood-prick life-chance print-out)partial	Newborn genome-sequencing programs now run at scale for treatable rare disease: New York's GUARDIAN study has sequenced over 20,000 babies since 2022 across 250+ conditions, and England's Generation Study had sequenced 12,286 newborns by 2025. The NHS announced in June 2025 a plan to sequence every newborn within a decade. None score life expectancy, behaviour or 'worth'; the readout exists, the destiny-scoring use does not. [source]	2025-06
✅	Reproductive selection against specific genetic conditions practiced at population scalepresent	Non-invasive prenatal testing (NIPT) is documented in at least 27 countries. A May 2024 meta-analysis found 69% of NIPT-flagged Down syndrome pregnancies were terminated, with modelling estimating a 30-54% reduction in Down syndrome live births across the US and Europe. This is real, at-scale selection, but against defined chromosomal conditions rather than trait ranking. [source]	2024-05
◐	Polygenic and genetic risk scores marketed to adult consumerspartial	23andMe sold polygenic risk reports for coronary artery disease and type 2 diabetes, and firms such as Allelica, Myriad and Ambry offer scores; in 2025 the European Society of Cardiology endorsed cautious clinical use alongside traditional tools. Adoption stays limited and contested, and 23andMe filed for Chapter 11 bankruptcy in March 2025. [source]	2025-07
◐	Genetic discrimination by insurers or employers is possible, and the law's answer is incompletepartial	The US Genetic Information Nondiscrimination Act (GINA, 2008) bars genetic discrimination in health insurance and employment, where documented cases remain few, but it explicitly exempts life, disability and long-term-care insurance. Florida became the first state to close that gap (law effective Jan 2021); Australia passed a total ban on genetic results in life insurance in April 2026 (effective 8 Oct 2026). The door Gattaca fears stays legally open for life insurers across most of the US. [source]	2026-04
—	Heritable (germline) genome editing used to create childrenabsent	It has happened once, illicitly: He Jiankui announced CRISPR-edited twins in November 2018, was jailed three years, released in April 2022, and is again running a lab. No jurisdiction sanctions heritable editing of embryos intended for birth; in May 2025 cell- and gene-therapy trade bodies called for a 10-year global moratorium. The technique exists; its use to make babies is banned and not practiced. [source]	2025-05
—	A genetic underclass, with DNA scores assigning jobs, status and life chancesabsent	No population is stratified by genome score into life outcomes. 'Genoism' is director Andrew Niccol's coinage for the film; the phrase 'genetic underclass' traces to a 1993 law-review warning about potential, not a documented reality. Prediction remains probabilistic, scores explain only a fraction of trait variance, and no jurisdiction permits ranking people by DNA for employment or social standing. As of mid-2026 this load-bearing wall of the nightmare does not exist. [source]	2026-07

The honest read

This board reads as parts-on-a-shelf, not a machine: the components of Gattaca largely exist (embryo scoring at 100-plus clinics, newborn genome programs, prenatal selection at population scale), but they have not been assembled into a caste system. The real barrier is not hardware. Two things hold: prediction stays probabilistic rather than deterministic, since polygenic scores explain only a fraction of any trait, and the law still forbids the core act of ranking people by DNA for jobs or status (GINA), even while it leaves life insurance exposed. On base rates, trait-optimization of embryos is a tiny, expensive, elective niche sold on thin evidence, not a norm; most real-world genetic selection today is against severe disease, which is a different moral object than genoism. The nightmare's engine, a society that agrees to let a genome score decide a life, is the part that does not exist, and that is the reassuring finding.